Pharmacological Strategies for Overcoming Multidrug Resistance to Chemotherapy

被引:2
|
作者
Fedotcheva, T. A. [1 ]
Shimanovsky, N. L. [1 ]
机构
[1] Pirogov Russian Natl Res Med Univ, 1 Ostrovityanova St, Moscow 117997, Russia
关键词
multidrug resistance; P-glycoprotein; MRP proteins; BCRP-protein; tyrosine kinase inhibitors; flavonoids; P-GLYCOPROTEIN; JAK2; INHIBITOR; CANCER-CELLS; CO-TREATMENT; GLUTATHIONE; TRANSPORTER; TARGETS;
D O I
10.1007/s11094-023-02790-8
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Actual mechanisms of multidrug resistance (MDR) to chemotherapy in oncology are considered. ABC-transporters such as P-glycoprotein, BCRP protein, and MRP proteins take part in the development of resistance. The review presents the main classes of chemosensitizers, i.e., inhibitors of ABC transporters of the 1(st)-4(th) generations. Plant polyphenols, i.e., flavonoids, are commonly referred to as the last (4(th)) generation of MDR inhibitors. Chemosensitizers of different classes should be chosen with allowance for the patient mutation-expression profile and the receptor status of a particular tumor. The appropriate dosage of the chemosensitizer and the administration schedule can enhance the process of counteracting MDR.
引用
收藏
页码:1307 / 1313
页数:7
相关论文
共 50 条
  • [31] PHARMACOLOGICAL CIRCUMVENTION OF MULTIDRUG-RESISTANCE
    FORD, JM
    HAIT, WN
    CYTOTECHNOLOGY, 1993, 12 (1-3) : 171 - 212
  • [32] Pharmacological considerations in the modulation of multidrug resistance
    Fisher, GA
    Lum, BL
    Hausdorff, J
    Sikic, BI
    EUROPEAN JOURNAL OF CANCER, 1996, 32A (06) : 1082 - 1088
  • [33] Editorial: Multidrug resistance in cancer: pharmacological strategies from basic research to clinical issues
    Riganti, Chiara
    Mini, Enrico
    Nobili, Stefania
    FRONTIERS IN ONCOLOGY, 2015, 5
  • [34] Paclitaxel/hydroxypropyl-β-cyclodextrin complex-loaded liposomes for overcoming multidrug resistance in cancer chemotherapy
    Shen, Qiying
    Shen, Yurun
    Jin, Feiyang
    Du, Yong-zhong
    Ying, Xiao-ying
    JOURNAL OF LIPOSOME RESEARCH, 2020, 30 (01) : 12 - 20
  • [35] Overcoming Chemotherapy Resistance in Prostate Cancer
    Madan, Ravi A.
    Pal, Sumanta Kumar
    Sartor, Oliver
    Dahut, William L.
    CLINICAL CANCER RESEARCH, 2011, 17 (12) : 3892 - 3902
  • [36] Overcoming cisplatin resistance in chemotherapy by biomineralization
    Chen, Wei
    Xiao, Yun
    Liu, Xueyao
    Chen, Yanhong
    Zhang, Jiaojiao
    Xu, Xurong
    Tang, Ruikang
    CHEMICAL COMMUNICATIONS, 2013, 49 (43) : 4932 - 4934
  • [37] Epigenetic approaches to overcoming chemotherapy resistance
    Strauss, Julius
    Figg, William D.
    LANCET ONCOLOGY, 2015, 16 (09): : 1013 - 1015
  • [38] The Potential Strategies for Overcoming Multidrug Resistance and Reducing Side Effects of Monomer Tubulin Inhibitors for Cancer Therapy
    Cui, Yingjie
    Zhang, Jing
    Zhang, Guifang
    CURRENT MEDICINAL CHEMISTRY, 2024, 31 (14) : 1874 - 1895
  • [39] Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies
    Li, Wen
    Zhang, Han
    Assaraf, Yehuda G.
    Zhao, Kun
    Xue, Xiaojun
    Xie, Jinbing
    Yang, Dong-Hua
    Chen, Zhe-Sheng
    DRUG RESISTANCE UPDATES, 2016, 27 : 14 - 29
  • [40] A synthetic antibiotic class overcoming bacterial multidrug resistance
    Mitcheltree, Matthew J.
    Pisipati, Amarnath
    Syroegin, Egor A.
    Silvestre, Katherine J.
    Klepacki, Dorota
    Mason, Jeremy D.
    Terwilliger, Daniel W.
    Testolin, Giambattista
    Pote, Aditya R.
    Wu, Kelvin J. Y.
    Ladley, Richard Porter
    Chatman, Kelly
    Mankin, Alexander S.
    Polikanov, Yury S.
    Myers, Andrew G.
    NATURE, 2021, 599 (7885) : 507 - +